Grove Bank & Trust Buys 694 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Grove Bank & Trust boosted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 72.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,653 shares of the biopharmaceutical company’s stock after acquiring an additional 694 shares during the quarter. Grove Bank & Trust’s holdings in Regeneron Pharmaceuticals were worth $1,276,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Nordea Investment Management AB boosted its stake in shares of Regeneron Pharmaceuticals by 118.1% in the 4th quarter. Nordea Investment Management AB now owns 137,321 shares of the biopharmaceutical company’s stock valued at $105,810,000 after purchasing an additional 74,350 shares in the last quarter. Green Alpha Advisors LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth about $294,000. New England Research & Management Inc. bought a new position in Regeneron Pharmaceuticals during the 4th quarter valued at about $386,000. MassMutual Private Wealth & Trust FSB lifted its holdings in Regeneron Pharmaceuticals by 9.8% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 11,103 shares of the biopharmaceutical company’s stock valued at $8,570,000 after purchasing an additional 994 shares during the last quarter. Finally, Crescent Sterling Ltd. acquired a new position in Regeneron Pharmaceuticals in the fourth quarter valued at about $215,000. 83.31% of the stock is owned by institutional investors.

Insider Transactions at Regeneron Pharmaceuticals

In other news, Director Huda Y. Zoghbi sold 1,638 shares of the business’s stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $781.33, for a total transaction of $1,279,818.54. Following the completion of the sale, the director owned 1,703 shares in the company, valued at $1,330,604.99. The trade was a 49.03% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction on Monday, February 9th. The shares were sold at an average price of $778.53, for a total value of $77,853.00. Following the transaction, the director directly owned 17,803 shares in the company, valued at $13,860,169.59. This trade represents a 0.56% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 5,274 shares of company stock worth $4,142,738. Insiders own 7.02% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

Shares of REGN stock opened at $732.87 on Friday. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $821.11. The company has a current ratio of 4.13, a quick ratio of 3.39 and a debt-to-equity ratio of 0.09. The firm’s 50 day moving average is $765.35 and its 200-day moving average is $700.68. The firm has a market capitalization of $77.48 billion, a price-to-earnings ratio of 17.63, a PEG ratio of 1.97 and a beta of 0.41.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share for the quarter, beating analysts’ consensus estimates of $10.74 by $0.70. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The business had revenue of $3.88 billion during the quarter, compared to analyst estimates of $3.76 billion. During the same quarter last year, the business posted $12.07 earnings per share. Regeneron Pharmaceuticals’s revenue for the quarter was up 2.5% compared to the same quarter last year. Sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, March 5th. Stockholders of record on Friday, February 20th were paid a $0.94 dividend. This is an increase from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. The ex-dividend date of this dividend was Friday, February 20th. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s payout ratio is 9.05%.

Analyst Ratings Changes

Several brokerages have weighed in on REGN. HSBC assumed coverage on shares of Regeneron Pharmaceuticals in a research note on Monday, November 24th. They set a “buy” rating and a $255.00 price objective on the stock. Wall Street Zen downgraded Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Sunday, March 8th. Barclays started coverage on Regeneron Pharmaceuticals in a research report on Friday, March 6th. They set an “overweight” rating and a $923.00 price target on the stock. Royal Bank Of Canada raised their price target on Regeneron Pharmaceuticals from $745.00 to $765.00 and gave the company a “sector perform” rating in a report on Monday, March 2nd. Finally, Evercore lifted their price objective on Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the company an “outperform” rating in a research report on Thursday, January 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $802.27.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.